Salivary gland neoplasm

Anatomy and locations

The salivary glands are classified as major and minor. The major glands are the parotid, the submandibular and the sublingual. Hundreds of minor salivary glands are scattered throughout the mucosa of the oral cavity and upper aerodigestive tract, including the hard and soft palate and regions near the nasal cavity. Tumour site influences clinical presentation, surgical approach and the likelihood that a lesion is malignant.

Types and pathology

Histologic subtypes are diverse. Common benign tumours include pleomorphic adenoma and Warthin tumour. Frequent malignant types include mucoepidermoid carcinoma and adenoid cystic carcinoma, but many other rarer subtypes exist. Tumours vary from well-circumscribed, slow-growing lesions to infiltrative cancers notable for perineural invasion, lymphatic spread or distant metastasis. Histologic grade and stage are key determinants of prognosis.

Epidemiology and risk factors

Salivary gland neoplasms are rare compared with other head and neck tumours. A higher proportion of tumours arising in major glands, particularly the parotid, are benign, while minor gland tumours have a greater likelihood of malignancy. Recognized risk factors include prior therapeutic radiation to the head and neck and certain occupational exposures; many cases occur without an identifiable cause.

Clinical presentation and diagnosis

Patients typically present with a palpable mass in the affected gland. Pain, rapid growth, facial weakness or numbness suggest malignancy or nerve involvement. Minor gland tumours may appear as mucosal lumps or ulcerations on the palate or oral mucosa. Evaluation usually combines clinical examination, imaging (ultrasound, MRI or CT) to assess extent and relation to neurovascular structures, and tissue diagnosis obtained by fine-needle aspiration or core biopsy.

Staging, treatment and prognosis

Treatment is guided by histology, grade and stage. Surgery is the cornerstone: procedures range from local excision of minor-gland lesions to superficial or total parotidectomy with preservation of the facial nerve when possible. Adjuvant radiotherapy is frequently recommended for high-grade, advanced or recurrent tumours. Chemotherapy has a limited and selective role, typically reserved for metastatic or unresectable disease. Prognosis depends on subtype and stage; many benign tumours are cured by excision, while some malignant types require long-term surveillance for late recurrence or spread.

Follow-up and multidisciplinary care

Long-term follow-up is important because certain salivary malignancies can recur years after initial treatment. Management often requires a multidisciplinary team including head and neck surgeons, radiation oncologists, pathologists and radiologists. Reconstruction, rehabilitation and attention to functional outcomes, including facial nerve function and salivary flow, are essential aspects of care.

Further resources

• Clinical overviews and consensus statements: salivary gland cancer overview.
• Anatomic descriptions and surgical approaches: references for the minor salivary glands, the submandibular region and the sublingual gland.
• Sites and mucosal minor glands such as the palate and areas near the nasal cavity.
• Epidemiology noting the predominance of tumours in the parotid gland.

For patients and clinicians, reliable specialty resources and multidisciplinary guidelines provide the most current recommendations for diagnosis, staging and management; primary literature and institutional protocols inform decisions in uncommon or complex cases.